Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis
- PMID: 23996639
- DOI: 10.1002/pros.22655
Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis
Abstract
Background: Despite an initial response to hormonal therapy, patients with advanced prostate cancer (PC) almost always progress to castration-resistant disease (CRPC). Although serum testosterone (T) is reduced by androgen deprivation therapy, intratumoral T levels in CRPC are comparable to those in prostate tissue of eugonadal men. These levels could originate from intratumoral conversion of adrenal androgens and/or from de novo steroid synthesis. However, the relative contribution of de novo steroidogenesis to AR-driven cell growth is unknown.
Methods: The relative contribution of androgen biosynthetic pathways to activate androgen receptor (AR)-regulated cell growth and expression of PSA, FKBP5, and TMPRSS2 was studied at physiologically relevant levels of adrenal androgen precursors and intermediates of de novo androgen biosynthesis in human prostate cancer cell lines, PC346C, VCaP, and LNCaP.
Results: In PC346C and VCaP, responses to pregnenolone and progesterone were absent or minimal, while large effects of adrenal androgen precursors were found. VCaP CRPC clones overexpressing CYP17A1 did not acquire an increased ability to use pregnenolone or progesterone to activate AR. In contrast, all precursors stimulated growth and gene expression in LNCaP cells, presumably resulting from the mutated AR in these cells.
Conclusions: Our data indicate that at physiological levels of T precursors PC cells can generally convert adrenal androgens, while de novo steroidogenesis is not generally possible in PC cells and is not able to support AR transactivation and PC growth.
Keywords: androgen-independent prostate cancer; androgen-responsive genes; precursors of testosterone; proliferation; real-time RT-PCR.
© 2013 Wiley Periodicals, Inc.
Similar articles
-
Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.Prostate. 2022 Apr;82(5):505-516. doi: 10.1002/pros.24297. Epub 2022 Jan 17. Prostate. 2022. PMID: 35037287 Free PMC article.
-
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.Cancer Res. 2011 Oct 15;71(20):6503-13. doi: 10.1158/0008-5472.CAN-11-0532. Epub 2011 Aug 25. Cancer Res. 2011. PMID: 21868758 Free PMC article.
-
Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.Cancer Res. 2010 Feb 1;70(3):1256-64. doi: 10.1158/0008-5472.CAN-09-2092. Epub 2010 Jan 19. Cancer Res. 2010. PMID: 20086173
-
Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.BJU Int. 2009 Aug;104(4):438-48. doi: 10.1111/j.1464-410X.2009.08695.x. Epub 2009 Jun 24. BJU Int. 2009. PMID: 19558559 Review.
-
New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.Expert Opin Investig Drugs. 2010 Jul;19(7):837-46. doi: 10.1517/13543784.2010.494178. Expert Opin Investig Drugs. 2010. PMID: 20524793 Review.
Cited by
-
Hedgehog Signaling for Urogenital Organogenesis and Prostate Cancer: An Implication for the Epithelial-Mesenchyme Interaction (EMI).Int J Mol Sci. 2019 Dec 20;21(1):58. doi: 10.3390/ijms21010058. Int J Mol Sci. 2019. PMID: 31861793 Free PMC article. Review.
-
Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.Prostate. 2022 Apr;82(5):505-516. doi: 10.1002/pros.24297. Epub 2022 Jan 17. Prostate. 2022. PMID: 35037287 Free PMC article.
-
Mechanisms of resistance in castration-resistant prostate cancer (CRPC).Transl Androl Urol. 2015 Jun;4(3):365-80. doi: 10.3978/j.issn.2223-4683.2015.05.02. Transl Androl Urol. 2015. PMID: 26814148 Free PMC article. Review.
-
Intracrine androgen biosynthesis and drug resistance.Cancer Drug Resist. 2020 Nov 3;3(4):912-929. doi: 10.20517/cdr.2020.60. eCollection 2020. Cancer Drug Resist. 2020. PMID: 35582223 Free PMC article. Review.
-
Clinical relevance of androgen receptor alterations in prostate cancer.Endocr Connect. 2017 Nov;6(8):R146-R161. doi: 10.1530/EC-17-0118. Endocr Connect. 2017. PMID: 29030409 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous